IDRSF / Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

Idorsia will publish its Nine-Month Financial Reporting 2023 on Tuesday October 24, 2023, at 07:00 CEST. An investor conference call and webcast will more_horizontal

Idorsia Ltd (OTC:IDRSF) Q2 2023 Earnings Conference Call July 25, 2023 9:00 AM ET Company Participants Andrew Weiss - Head of IR Jean-Paul Clozel - CE more_horizontal

Idorsia will publish its half year financial results 2023 on Tuesday July 25, 2023, at 07:00 CEST. An investor conference call and webcast will be hel more_horizontal

Idorsia reported the yearly results for 2022 with some very positive developments, while also discussing important risk factors. Clazosentan will not more_horizontal

Idorsia Ltd (OTCPK:IDRSF) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Representatives Jean-Paul Clozel - Chief Executive Offi more_horizontal

Idorsia is a Swiss biopharmaceutical company with multiple commercial and pre-commercial assets. Idorisa's lead asset Daridorexant seems to be a more more_horizontal

Idorsia's stock is testing its most important overhead resistance and is trying to break out from its long-term downtrend, a rare situation that could more_horizontal

QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan) are now commercialized by Idorisa, and Johnson & Johnson is distributing Ponvory (Ponesimod). The Swis more_horizontal